Genetic susceptibility to adverse drug effects - Epidemiology ...

More documents

Recommendations

Info

General discussion QTc interval in the Rotterdam Study. Circulation 2007;116(1):10-6. 76. Post W, Shen H, Damcott C, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered 2007;64(4):214-9. 77. Lajoix AD, Reggio H, Chardes T, et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic betacells controls insulin secretion. Diabetes 2001;50(6):1311-23. 78. Kingwell BA, Formosa M, Muhlmann M, et al. Nitric oxide synthase inhibition reduces glucose uptake during exercise in individuals with type 2 diabetes more than in control subjects. Diabetes 2002;51(8):2572-80. 79. Gunawardana SC, Rocheleau JV, Head WS, et al. Mechanisms of time-dependent potentiation of insulin release: involvement of nitric oxide synthase. Diabetes 2006;55(4):1029-33. 80. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989;54(2):87-143. 81. Boyd AE, 3rd, Aguilar-Bryan L, Nelson DA. Molecular mechanisms of action of glyburide on the beta cell. Am J Med 1990;89(2A):3S-10S; discussion 51S-3S. 82. Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51 Suppl 3:S368- 76. 83. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:Suppl:789-830. 84. Schor S. The University Group Diabetes Program. A statistician looks at the mortality results. Jama 1971;217(12):1671-5. 85. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21(9):976-9. 86. Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. Jama 1971;217(12):1676-87. 87. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53. 88. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 2001;133(1):193-9. 89. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000;14(4):192-6. 90. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88(2):531-7. 91. Legtenberg RJ, Houston RJ, Oeseburg B, et al. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol 2001;419(1):85-92. 92. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103(25):3111-6. 93. Yokoshiki H, Sunagawa M, Seki T, et al. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 1998;274(1 Pt 1):C25-37. 94. Venkatesh N, Lamp ST, Weiss JN. Sulfonylureas, ATP-sensitive K+ channels, and cellular K+ loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991;69(3):623-37. 95. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996;94(9):2297-301. 96. Clayton DHM. Time-varying explanatory variables. In: Statistical models in epidemiology: Oxford University Press; 1993:307-18. 97. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005;78(6):559-81. 98. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33(1):30-42. 99. Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol 2006;163(5):397-403. 100. Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 167
Chapter 6 2007;356(11):1094-7. 101. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6(2):95-108. 102. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234(1):4- 33. 168
Page 1 and 2:
Genetic susceptibility to adverse d
Page 3 and 4:
The work presented in this thesis w
Page 5:
Promotiecommissie Promotoren: Prof.
Page 10:
1 General Introduction
Page 13 and 14:
Chapter 1 genome. Every SNP represe
Page 15 and 16:
Chapter 1 References 1. 2. 3. 4. 5.
Page 18:
2 Quantifying the risk of adverse d
Page 21 and 22:
Chapter 2 Introduction The cardiac
Page 23 and 24:
Chapter 2 Table 1 Characteristics o
Page 25 and 26:
Chapter 2 digoxin treatment appears
Page 27 and 28:
Chapter 2 References 1. 2. 3. 4. 5.
Page 30:
3 Common variants in the ABCB1 gene
Page 33 and 34:
Chapter 3.1 Introduction The ATP-Bi
Page 35 and 36:
Chapter 3.1 Co-variables. Covariate
Page 37 and 38:
Chapter 3.1 Table 3 Frequencies of
Page 39 and 40:
Chapter 3.1 Table 5 Risk of serum d
Page 41 and 42:
Chapter 3.1 Table 6 Other studies o
Page 43 and 44:
Chapter 3.1 References 1. 2. 3. 4.
Page 46 and 47:
3.2 Common ABCB1 variants increase
Page 48 and 49:
Common ABCB1 variants increase QTc
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58:
Page 61 and 62:
Chapter 3.3 Introduction The quinol
Page 63 and 64:
Chapter 3.3 In addition to the diar
Page 65 and 66:
Chapter 3.3 Table 1 General charact
Page 67 and 68:
Chapter 3.3 confounding by contrain
Page 69 and 70:
Chapter 3.3 adverse effects of mefl
Page 71 and 72:
Page 74:
4 Common variants in the NOS1AP gen
Page 77 and 78:
Chapter 4.1 Introduction Sudden car
Page 79 and 80:
Chapter 4.1 Assessment of QTc inter
Page 81 and 82:
Chapter 4.1 Table 1 Baseline charac
Page 83 and 84:
Chapter 4.1 Table 3 Number of indiv
Page 85 and 86:
Chapter 4.1 ditional GG haplotype c
Page 87 and 88:
Page 90 and 91:
4.2 Common NOS1AP variants potentia
Page 92 and 93:
Common NOS1AP variants potentiate d
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102:
Page 105 and 106:
Chapter 4.3 Introduction In the pas
Page 107 and 108:
Chapter 4.3 Figure 1 Flowdiagram of
Page 109 and 110:
Chapter 4.3 Table 1 Characteristics
Page 111 and 112:
Chapter 4.3 Table 2 Cardiovascular
Page 113 and 114:
Chapter 4.3 Table 3 Drugs, NOS1AP a
Page 115 and 116:
Chapter 4.3 found indication that t
Page 117 and 118: Chapter 4.3 References 1. 2. 3. 4.
Page 120 and 121: 4.4 Common variation in the NOS1AP
Page 122 and 123: Common variants in the NOS1AP gene
Page 132: Common variants in the NOS1AP gene
Page 136 and 137: 5 Effect of ABCB1 and NOS1AP genoty
Page 138 and 139: Effect of ABCB1 and NOS1AP genotype
Page 150: Effect of ABCB1 and NOS1AP genotype
Page 154 and 155: 6 General discussion Despite all re
Page 156 and 157: General discussion ening properties
Page 158 and 159: General discussion or the excess [C
Page 160 and 161: General discussion continuously mon
Page 162 and 163: General discussion cardiovascular d
Page 164 and 165: General discussion for non-cardiova
Page 166 and 167: General discussion 25. 26. 27. 28.
Page 170: General discussion 169
Page 174 and 175: 7.1 Summary Despite all research ef
Page 176: Summary reduced mortality in patien
Page 179 and 180: Chapter 7.2 steeds aanzienlijk is e
Page 182 and 183: 8 Dankwoord Een proefschrift schrij
Page 184: Dankwoord Bijzondere dank aan alle
Page 188 and 189: 10 Bibliography Manuscripts based o
Page 190: Bibliography Van der Hooft CS, Diel
show all

Genetic susceptibility to adverse drug effects - Epidemiology ...

Create successful ePaper yourself

Delete template?

Save as template?